Many Roles of CCL20: Emphasis on Breast Cancer.
Many Roles of CCL20: Emphasis on Breast Cancer.
复制标题
DOI：
10.14304/surya.jpr.v2n3.2
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Kingsley O. Osuala;Bonnie F. Sloane
中科院分区：
文献类型：
--
作者：
Kingsley O. Osuala;Bonnie F. Sloane
CCL20或MIP3α是一种小~8 kDa的蛋白质，主要在肝脏、结肠、前列腺、宫颈和皮肤中表达。CCL20的细胞受体是CCR6。与许多其他细胞因子不同，CCL20只与CCR6结合，使CCL20/CCR6途径成为一个有吸引力的药物靶点。自从20世纪90年代初S首次发现CCL20以来，越来越多的证据表明趋化因子及其受体与许多疾病有关，包括类风湿性关节炎和人类免疫缺陷病毒感染。CCL20还与卵巢癌、结直肠癌和胰腺癌等恶性肿瘤有关。CCL20还可以吸引促进肿瘤免疫抑制的细胞进入肿瘤微环境，这可能有助于肿瘤的免疫逃避能力和肿瘤的进展。
CCL20 or MIP3α is a small ~8 kDa protein primarily expressed in the liver, colon, prostate, cervix, and skin. The cellular receptor for CCL20 is CCR6. CCl20 unlike many other cytokines only binds CCR6, making the CCL20/CCR6 pathway an attractive drug target. Since the initial discovery of CCL20 in the early 1990's, there has been an increase in the evidence implicating the chemokine and its receptor in a number of diseases, including rheumatoid arthritis and human immunodeficiency virus infection. CCL20 has also been linked to malignancies such as ovarian, colorectal and pancreatic cancers. CCL20 can also attract tumor-promoting immune-suppressive cells to the tumor microenvironment, which may contribute to the immune evasive potential of the tumor and tumor progression.